Ryozo Sakoda

This inventor holds 25 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Nissan Chemical Industries Limited, Sagami Chemical Research Center. Active years: 1980-1996.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ryozo Sakoda. Retrieved from https://idiyas.com/inventor/ryozo-sakoda

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 8

Forward Citations = 212(Granted Patents)

Location History:

Kashiwa, JP (1986 - 1992)
Funabashi, JP (1980 - 1996)

Company Filing History:

25 out of 1,235

Nissan Chemical Industries Limited

patents

2 out of 191

Sagami Chemical Research Center

patents

where one patent can have more than one assignee

Years Active: 1980-1996

Loading Chart...

Areas of Expertise:

Pyridazinones

Antitumor Drug

Optical Resolution

Drug Effect Enhancer

Phosphonic Acid

Atherosclerosis

Anti-Allergic Agent

Hydrazine Derivatives

Platinum Film

Dihydropyridine

Anthranylaldehyde

Pyranobenzoxadiazole

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5508403 - Phosphorus pyridine compound (1996-04-16),

2. 5319089 - Process for the optical resolution of pyranobenzoxadiazole compounds (1994-06-07),

3. 5318968 - 5-heteroarylamino-6-oxy-substituted 3(2H)-pyridazinones (1994-06-07),

4. 5314883 - 5-heteroarylamino-6-oxy-substituted 3(2H)-pyridazinones (1994-05-24),

5. 5304550 - Drug effect-enhancing agent for antitumor drug (1994-04-19),

6. 5272271 - Pyranobenzoxadiazole derivatives (1993-12-21),

7. 5202323 - 5-arylmethylamino-6-oxy-substituted 3(2H)-pyridazinones (1993-04-13),

8. 5177237 - Hydrazine derivatives useful as intermediates in the synthesis of (1993-01-05),

9. 5130303 - Drug effect-enhancing agent for antitumor drug (1992-07-14),

10. 5100702 - Thin platinum film-forming composition (1992-03-31),

11. 5098900 - 3(2H)pyridazinone, process for its preparation and anti-allergic agent (1992-03-24),

12. 5097037 - Process for the optical resolution of pyranobenzoxadiazole compounds (1992-03-17),

13. 4978665 - 3(2H)pyridazinone, and antagonistic agent against SRS-A containing it (1990-12-18),

14. 4900752 - Pyranobenzoxadiazole derivatives (1990-02-13),

15. 4892947 - 3(2H)Pyridazinone, process for its preparation and anti-allergic agent (1990-01-09),

Title: Ryozo Sakoda: A Pioneer in Pharmaceutical Innovations

Introduction: Ryozo Sakoda, located in Funabashi, Japan, is an accomplished inventor with a remarkable portfolio of 25 patents. His innovative contributions, particularly in the fields of pharmaceuticals and chemical compounds, have significantly advanced drug development and treatment efficacy.

Latest Patents: Among Sakoda's latest patents is a groundbreaking phosphorus pyridine compound that serves as an agent for enhancing the drug effects of an antitumor medication. This compound, described by a specific formula, represents a novel approach in cancer treatment. Additionally, he developed a process for the optical resolution of pyranobenzoxadiazole compounds, which involves reacting the compound with an optically active carboxylic acid and subsequently separating the diastereomeric salt. These inventions demonstrate his dedication to improving pharmaceutical technologies and drug therapies.

Career Highlights: Throughout his career, Ryozo Sakoda has made significant strides in the field of chemistry and pharmaceuticals. He has worked with renowned companies such as Nissan Chemical Industries Limited and Sagami Chemical Research Center. His expertise in developing advanced chemical processes has set him apart as a leading innovator in his industry.

Collaborations: Sakoda has collaborated with esteemed colleagues, including Kiyotomo Seto and Keizo Tanikawa. Their joint efforts have contributed to the effectiveness and efficiency of the innovative processes and compounds they developed together.

Conclusion: Ryozo Sakoda's extensive work and patent portfolio reflect his significant influence in pharmaceutical innovations. Through his dedication and collaborative spirit, he continues to propel advancements in drug development, ensuring better outcomes for patients and the medical community at large.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]